NSE filing, NSE: SENORES. Summary written from the filing by ALFA Finder's alert engine.
Senores Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,119.00
- Market cap
- ₹5,153 Cr
- Revenue (annual)
- ₹632.6 Cr
- Net profit (annual)
- ₹115.4 Cr
- P/E (TTM)
- 38.6×Sector 48.6×
- Promoter holding
- 45.82%+0.00% QoQ
- FII holding
- 6.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Senores Pharmaceuticals Ltd
All →Senores Pharmaceuticals Regulatory Approval
Senores Pharmaceuticals disclosed that its subsidiary Ratnatris Pharmaceuticals' Mehsana facility received PIC/S GMP certification from Ukraine's SMDC. The certificate, issued 16 November 2026, opens a wider pathway to regulatory approvals.
Senores Pharmaceuticals Earnings Call Transcript: Key Takeaways
Senores delivered record quarterly revenue and EBITDA, driven by US portfolio expansion and regulated market growth.
- Call
- Guides 40% growth
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals reported no deviation in utilising the Rs 95 Crore raised via a preferential warrant issue for the quarter ended September 30, 2026. Audit Committee reviewed the statement and the Board took it on record.
- Value
- ₹95.00 Cr
Senores Pharmaceuticals Capacity Expansion: ₹20 Cr Investment
Senores Pharmaceuticals' subsidiary Apnar Pharma Private Limited plans a 0.7 Bn unit capacity addition by March 2027. The investment is Rs.20.00 Crore, funded by internal accruals and IPO proceeds.
- Value
- ₹20.00 Cr
- Execution
- By end of March 2027
- production capacity
- 0.7 Bn units
Senores Pharmaceuticals Capacity Expansion: ₹18 Cr Investment
Senores Pharmaceuticals plans to add 0.8 Bn units of capacity to its existing 1.2 Bn unit plant by March 2027. The investment is Rs.18.00 Crore, funded by internal accruals and IPO proceeds.
- Value
- ₹18.00 Cr
- Execution
- By end of March 2027
- production capacity
- 0.8 Bn units
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals appointed Talati and Talati LLP as Statutory Auditor for a 60-month term, effective 29 October 2026. The appointment was approved at the board meeting held the same day.
- Execution
- 60 months
Other annual general meeting announcements
All →Affordable Robotic & Automation Annual General Meeting
Affordable Robotic seeks postal ballot approval for a Rs.200 Crore related-party limit, loan and guarantee authority, and borrowing powers. E-voting closes 19 December 2026.
Cera Sanitaryware Annual General Meeting
Cera Sanitaryware seeks postal ballot approval to re-appoint Vikram Somany as Chairman and MD, and Anandh Sundar as Independent Director. E-voting closes 18 December 2026.
OnEMI Technology Solutions Annual General Meeting
OnEMI Technology Solutions (Kissht) seeks shareholder approval via postal ballot to appoint Venkatadri Chandrasekaran as Non-Executive Independent Director for 3 years. E-voting closes 18 December 2026.
United Polyfab Gujarat Annual General Meeting
United Polyfab Gujarat's EGM on 18 November 2026 considered three independent director appointments. Results are pending the scrutiniser's report.
Tamil Nadu Newsprint And Papers Annual General Meeting
TNPL issued a postal ballot notice seeking member approval to re-appoint an independent director and appoint a new director. E-voting runs from 19 November to 18 December 2026.
Electrotherm (India) Annual General Meeting
Electrotherm sought shareholder approval by postal ballot to vary the powers of Executive Vice Chairman Shailesh Bhandari. E-voting runs from 20 November to 19 December 2026.